Certolizumab pegol: An evidence-based review of its place in the treatment of Crohn's disease

Core Evidence

Volumn 2, Issue 3, 2008, Pages 209-224

  Cassinotti, Andrea ^a   Ardizzone, Sandro ^a   Porro, Gabriele Bianchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti TNF; Biological therapy; Certolizumab pegol; Crohn's disease

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE DERIVATIVE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL MASS; ABDOMINAL PAIN; ANTIBODY SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BREAST HYPERPLASIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; CROHN DISEASE; DEMYELINATING DISEASE; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED PRACTICE; EYE DISEASE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; LIVER TOXICITY; LUPUS VULGARIS; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NONHUMAN; OSTEOPOROSIS; PARALYTIC ILEUS; PERIANAL ABSCESS; PHARMACODYNAMICS; PRURITUS; QUALITY OF LIFE; RECTUM HEMORRHAGE; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ULCER; TERATOGENICITY; THORAX PAIN; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ACUITY; VOMITING;

EID: 65849438617     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: New insights into pathogenesis and treatment. J Intern Med. 2002a; 252:4675-4696.
2. Ardizzone S, Colombo E, Maconi G, et al. Infliximab in treatment of Crohn's disease: The Milan experience. Dig Liv Dis. 2002b;34:411-418.
3. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs. 2005;65:2253-2286.
4. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
5. Baker M, Stringer F, Stephens P. Pharmacokinetic properties of the anti-TNF agent certolizumab pegol. Ann Rheum Dis. 2006;65(Suppl. II):175.
6. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
7. Blick SKA, Curran MP. Certolizumab pegol in Crohn's disease. Biodrugs. 2007;21:195-201.
8. Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2006a;9:221-233.
9. Blonski W, Lichtenstein GR. Complication of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol. 2006b;22:30-43.
10. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
11. Breese E, McDonald TT. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol. 1995;371:821-824.
12. Cammà C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-1473.
13. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
14. Caprilli R, Angelucci E, Cocco A, et al. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Goup for IBD (IG-IBD) position statement. Dig Liv Dis. 2005a;37:407-417.
15. Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig Liv Dis. 2005b;37:973-979.
16. Chang JT, Lichtenstein GR. Drug insight: Antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nature Clin Practice Gastroenterol Hepatol. 2006;3:220-228.
17. Chapman AP. Pegylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev. 2002;54:531-545.
18. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology. 2002;41:1133-1137.
19. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
20. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology. 2007a;132:52-65.
21. Colombel JF, Hanauer SB, Sandborn WJ, Panes J, Schreiber S. Certolizumab pegol is effective in patients regardless of CRP level and disease duration: Data from PRECiSE 2. J Crohn's Colitis. 2007b;1:8. Abstract P018.
22. Colombel JF, Hanauer S, Sandborn WJ, Panes J, Schreiber S. Subcutaneous certolizumab pegol is effective in patients with prior infliximab exposure or concomitant immunosuppressant or glucocorticoid treatment: data from PRECiSE 2. J Crohn's Colitis. 2007c;1:8. Abstract P019.
23. Colombel J, Schreiber S, Hanauer SB, et al. Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: Results from PRECiSE 3 and 4. Gastroenterology. 2007d;132:(Suppl. 2):A503. Abstract T1267.
24. Crofskey S. Certolizumab pegol a PRECiSE treatment for Crohn's disease. Inpharma. 2006;1547:7-8.
25. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology. 2003;124:917-924.
26. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology. 2001;123:255-260.
27. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease: The North American Crohn's Disease Study Group Investigators. N Engl J Med. 1995;332:292-297.
28. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's Disease Study Group Investigators. N Engl J Med. 2000;342:1627-1632.
29. Feagan B, Brown M, Gerlier L, Schreiber S. Certolizumab pegol improves work productivity and the ability to perform daily activities in patients with Crohn's disease: Data from PRECiSE 2. J Crohn's Colitis. 2007a;1:7. Abstract P011.
30. Feagan B, Coteur G, Keininger DL, Schreiber S. Certolizumab pegol 400 mg every 4 weeks improved health-related quality of life in patients with Crohn's disease in PRECiSE 2. J Crohn's Colitis. 2007b;1:9. Abstract P020.
31. Feagan BG, Sandborn WJ, Brown M, et al. Confirmed benefits of work productivity and daily activities of certolizumab pegol in Crohn's disease patients: Data from PRECiSE 1. Gastroenterology. 2007c;132:(Suppl. 2):A-507. Abstract T1285.
32. Fefferman DS, Farrell RJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:497-503
33. Fossati G, Nesbitt AM. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab and certolizumab pegol. Am J Gastroenterol. 2005a;100(Suppl.):S299.
34. Fossati G, Nesbitt AM. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). Presented at: American College of Gastroenterology 70th Annual Scientific Meeting; October 28-November 2, 2005b; Honolulu, Hawaii. Abstract 513.
35. Fossati G, Nesbitt A. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol. 2005c;100(Suppl. 2):A-697.
36. Fossati G, Brown D, Nesbitt A. Lipopolysaccharide-induced cytokine production: The effects of certolizumab pegol, etanercept, adalimumab and infliximab. J Crohn's Colitis. 2007;1:43. Abstract P151.
37. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
38. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody response to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553
39. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
40. Henry AJ, Kennedy J, Fossati G, et al. Stoichiometry of binding and complex formation with TNF by certolizumab pegol, adalimumab, and infliximab and the biologic effects of these complexes. Gastroenterology. 2007;132:(Suppl. 2): A-231. Abstract S1609.
41. Hommes D, Baert F, van Assche G, et al. The ideal management of CD: Top down versus step up strategies: A randomized controlled trial. Gastroenterology. 2006;130:A108. Abstract 749.
42. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cell to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;163:1081-1090.
43. Lewis JD. Anti-TNF antibodies for Crohn's disease - in pursuit of the perfect clinical trial. N Engl J Med. 2007;357:96-98.
44. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853.
45. Lowenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease. Drugs. 2006;66:1431-1439.
46. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
47. Murch SH, Braegger CP, Walzer-Smith JA, MacDonald TT. Localisation of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34:1705-1709.
48. Nesbitt AM, Henry AJ. High affinity and potency of the pegylated Fab' fragment CDP870 - a direct comparison with other anti-TNF agents. Gut. 2004;53(Suppl. VI). Abstract 47.
49. Oikonomou I, Shen B. Are we moving forward in the biological treatment of Crohn's disease? Time will tell. Inflamm Bowel Dis. 2006;12:147-149.
50. Orlando A, Colombo E, Kohn A, et al. Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study. Dig Liv Dis. 2005;37:577-583.
51. Papadakis KA, Targan SR. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148-1157.
52. Plosker GL, Lyseng-Williamson KA. Adalimumab in Crohn's disease. Biodrugs. 2007;21:125-132.
53. Podolski DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-428.
54. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987
55. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181.
56. Rose-John S, Schooltink H. CDP-870. Curr Opin Invest Drugs. 2003;4:588-592.
57. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610.
58. Rutgeerts P, Sandborn WJ, Enns R, et al. Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: Results of the GAIN study. Gut. 2006;55(Suppl. V):A20. Abstract OP-G-86.
59. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut. 2007a;56:1232-1239.
60. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007b;357:228-238
61. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results. Gastroenterology. 2007c;132:4(Suppl. 2):A-505. Abstract T1274.
62. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
63. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005a;129:807-818.
64. Schreiber S, Khaliq-Kareemi M, Lawrence I, et al. Certolizumab pegol, a humanised anti-TNF pegylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: A phase III study (PRECiSE 2). Gut. 2005b;54(Suppl. VII). Abstract 82.
65. Schreiber S, Colombel JF, Panes J, Scholmenrich J, McColm J, Sandborn WJ. Recent-onset Crohn's disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: Results from an analysis of the PRECiSE 2 phase III study. Presented at: 14th United European Gastroenterology Week; October 21-25, 2006; Berlin, Germany.
66. Schreiber S, Feagan BG, Hanauer SB, Rutgeerts P, Sandborn WJ. Subcutaneous certolizumab pegol is well tolerated by patients with active Crohn's disease: Results from two phase III studies (PRECISE 1 and 2). J Crohn's Colitis. 2007a;1:9. Abstract P021.
67. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007b;357:239-250.
68. Schreiber S, Hanauer SB, Feagan BG, et al. Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: The PRECiSE 3 efficacy results. Gastroenterology. 2007c;132(Suppl. 2):A-504. Abstract T1271.
69. Shanahan F. Crohn's disease. Lancet. 2002;359:62-69.
70. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004;126:1257-1269.
71. Targan SR, Hanauer SB, van Deventer SJ, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
72. Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
73. Travis SP, Stange EF, Lemann M, et al. European Crohn's and Colitis Organisation. European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. Gut. 2006;55(Suppl. 1):i16-i35.
74. Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol. 2006;22:370-376.
75. Van den Brande JMH, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut. 2007;56:509-517.
76. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
77. Vetterlein OM, Kopotsha T, Nesbitt AM, et al. Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol. Gut. 2006;55(Suppl. V):A133. Abstract MON-G-261.
78. Vetterlein OM, Nesbitt AM, Stephens S. Antibodies to certolizumab pegol in patients with Crohn's disease do not cross-react with adalimumab, etanercept, or infliximab. Gastroenterology. 2007;132:4(Suppl. 2):A-556. Abstract T1784.
79. Weir AN, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson AD. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans. 2002;30:512-516.
80. Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized pegylated Fab' fragment anti-tumor necrosis factor-a monoclonal antibodies. Therapy. 2006;3:535-545.
81. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a pegylated Fab' fragment of a humanized antitumor necrosis factor antibody, in patients with moderate to severe Crohn's disease: An exploratory study. Aliment Pharmacol Ther. 2004;20:1337-1346
82. Winter TA, de Villiers WJS, Mardini HE. CDP870 in Crohn's disease: reconsidering endpoints. Inflamm Bowel Dis. 2006;12:249.
83. Zalipsky S. Functionalized polyethylene glycol for preparation of biologically relevant conjugates. Bioconjug Chem. 1995;6:150-165.